Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 4.1 %

Shares of BTX stock opened at $0.33 on Thursday. The firm’s fifty day moving average price is $0.52 and its two-hundred day moving average price is $1.18. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The firm has a market capitalization of $19.40 million, a P/E ratio of -0.15 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.